Companies / Vertex Pharmaceuticals Inc / Ma / Activity
Activity — Vertex Pharmaceuticals Inc / Ma
144 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | Garber Alan M Director | Grant | Common Stock | $0 | +472 +6.87% | 7,344 <0.01% of shares | low |
| Feb 17, 2026 | Bunnage Mark E. Executive | Grant | Common Stock | $0 | +3K +24.31% | 13,215 <0.01% of shares | low |
| Feb 17, 2026 | McKechnie Duncan Executive | Grant | Common Stock | $0 | +5K +25.41% | 24,490 <0.01% of shares | low |
| Jan 22, 2026 | McKechnie Duncan Executive | Grant | Common Stock | $0 | +2K +9.97% | 22,938 <0.01% of shares | low |
| Jan 22, 2026 | McKechnie Duncan Executive | Grant | Common Stock | $0 | +5K +29.25% | 20,858 <0.01% of shares | low |
| Feb 17, 2026 | Atkinson Edward Morrow III Executive | Grant | Common Stock | $0 | +5K +24.63% | 25,105 <0.01% of shares | low |
| Jan 22, 2026 | Atkinson Edward Morrow III Executive | Grant | Common Stock | $0 | +4K +18.68% | 24,669 <0.01% of shares | low |
| Jan 22, 2026 | Atkinson Edward Morrow III Executive | Grant | Common Stock | $0 | +4K +23.34% | 20,786 <0.01% of shares | low |
| Feb 17, 2026 | Ambrose Kristen Executive | Grant | Common Stock | $0 | +2K +20.71% | 10,543 <0.01% of shares | low |
| Jan 22, 2026 | Ambrose Kristen Executive | Grant | Common Stock | $0 | +1K +12.04% | 12,095 <0.01% of shares | low |
| Jan 22, 2026 | Ambrose Kristen Executive | Grant | Common Stock | $0 | +3K +37.60% | 10,795 <0.01% of shares | low |
| Feb 17, 2026 | Bozic Carmen Executive | Grant | Common Stock | $0 | +5K +14.12% | 43,428 0.02% of shares | low |
| Jan 22, 2026 | Bozic Carmen Executive | Grant | Common Stock | $0 | +3K +8.55% | 44,002 0.02% of shares | low |
| Jan 22, 2026 | Bozic Carmen Executive | Grant | Common Stock | $0 | +8K +24.08% | 40,535 0.02% of shares | low |
| Feb 17, 2026 | Tatsis Ourania Executive | Grant | Common Stock | $0 | +6K +12.55% | 51,921 0.02% of shares | low |
| Jan 22, 2026 | Tatsis Ourania Executive | Grant | Common Stock | $0 | +4K +7.74% | 54,042 0.02% of shares | low |
| Jan 22, 2026 | Tatsis Ourania Executive | Grant | Common Stock | $0 | +8K +18.60% | 50,159 0.02% of shares | low |
| Feb 17, 2026 | Biller Jonathan Executive | Grant | Common Stock | $0 | +4K +24.56% | 20,973 <0.01% of shares | low |
| Jan 22, 2026 | Biller Jonathan Executive | Grant | Common Stock | $0 | +3K +12.84% | 24,374 <0.01% of shares | low |
| Jan 22, 2026 | Biller Jonathan Executive | Grant | Common Stock | $0 | +6K +41.12% | 21,600 <0.01% of shares | low |
| Feb 17, 2026 | Kewalramani Reshma CEO | Grant | Common Stock | $0 | +16K +12.23% | 149,813 0.06% of shares | low |
| Jan 22, 2026 | Kewalramani Reshma CEO | Grant | Common Stock | $0 | +12K +8.31% | 154,825 0.06% of shares | low |
| Jan 22, 2026 | Kewalramani Reshma CEO | Grant | Common Stock | $0 | +27K +23.26% | 142,940 0.06% of shares | low |
| Jan 22, 2026 | Altshuler David Executive | Grant | Common Stock | $0 | +3K +10.68% | 34,477 0.01% of shares | low |
| Jan 22, 2026 | Altshuler David Executive | Grant | Common Stock | $0 | +8K +33.78% | 31,149 0.01% of shares | low |
| Feb 17, 2026 | Sachdev Amit Executive | Grant | Common Stock | $0 | +6K +8.85% | 71,182 0.03% of shares | low |
| Jan 22, 2026 | Sachdev Amit Executive | Grant | Common Stock | $0 | +4K +5.79% | 70,998 0.03% of shares | low |
| Jan 22, 2026 | Sachdev Amit Executive | Grant | Common Stock | $0 | +8K +13.28% | 67,115 0.03% of shares | low |
| Feb 17, 2026 | Leiden Jeffrey M Executive | Grant | Common Stock | $0 | +8K +25.03% | 41,308 0.02% of shares | low |
| Jan 22, 2026 | Leiden Jeffrey M Executive | Grant | Common Stock | $0 | +9K +37.51% | 33,039 0.01% of shares | low |
| Feb 17, 2026 | Wagner Charles F Jr Executive | Grant | Common Stock | $0 | +7K +16.85% | 51,080 0.02% of shares | low |
| Jan 22, 2026 | Wagner Charles F Jr Executive | Grant | Common Stock | $0 | +4K +8.82% | 51,325 0.02% of shares | low |
| Jan 22, 2026 | Wagner Charles F Jr Executive | Grant | Common Stock | $0 | +9K +25.02% | 47,165 0.02% of shares | low |
| Feb 27, 2026 | Kewalramani Reshma CEO | Sell | Common Stock | $57.8K | -120 -0.09% | 137,758 0.05% of shares | low |
| Feb 25, 2026 | Ambrose Kristen Executive | Sell | Common Stock | $108.5K | -223 -3.10% | 6,981 <0.01% of shares | medium |
| Feb 27, 2026 | Kewalramani Reshma CEO | Sell | Common Stock | $115.9K | -240 -0.17% | 137,518 0.05% of shares | medium |
| Feb 25, 2026 | Tatsis Ourania Executive | Sell | Common Stock | $126.5K | -260 -0.55% | 46,763 0.02% of shares | medium |
| Feb 13, 2026 | Bhatia Sangeeta N. Director | Sell | Common Stock | $133.0K | -266 -5.83% | 4,299 <0.01% of shares | medium |
| Feb 26, 2026 | Ambrose Kristen Executive | Sell | Common Stock | $172.6K | -357 -5.11% | 6,624 <0.01% of shares | medium |
| Feb 18, 2026 | Tatsis Ourania Executive | Sell | Common Stock | $174.3K | -368 -0.75% | 48,650 0.02% of shares | medium |
| Feb 27, 2026 | Kewalramani Reshma CEO | Sell | Common Stock | $191.9K | -400 -0.29% | 137,878 0.05% of shares | medium |
| Feb 11, 2026 | Tatsis Ourania Executive | Sell | Common Stock | $214.6K | -466 -0.90% | 51,436 0.02% of shares | medium |
| Feb 27, 2026 | Kewalramani Reshma CEO | Sell | Common Stock | $225.1K | -460 -0.35% | 131,270 0.05% of shares | medium |
| Feb 24, 2026 | Ambrose Kristen Executive | Other | Common Stock | $264.9K | -546 -7.05% | 7,204 <0.01% of shares | low |
| Feb 10, 2026 | Ambrose Kristen Executive | Other | Common Stock | $277.3K | -592 -4.89% | 11,503 <0.01% of shares | low |
| Feb 24, 2026 | Bunnage Mark E. Executive | Other | Common Stock | $282.3K | -582 -6.86% | 7,904 <0.01% of shares | low |
| Feb 17, 2026 | Ambrose Kristen Executive | Other | Common Stock | $289.3K | -598 -5.67% | 9,945 <0.01% of shares | low |
| Feb 17, 2026 | Tatsis Ourania Executive | Sell | Common Stock | $298.1K | -609 -1.23% | 49,018 0.02% of shares | medium |
| Feb 25, 2026 | Bunnage Mark E. Executive | Sell | Common Stock | $301.5K | -620 -7.84% | 7,284 <0.01% of shares | medium |
| Feb 18, 2026 | Ambrose Kristen Executive | Sell | Common Stock | $302.2K | -638 -7.61% | 7,750 <0.01% of shares | medium |